SKINIPEDIA - Skin Diseases & Conditions: Palpable Purpura

Skin Diseases and Conditions: Palpable Purpura case study by SALVADOR ARIAS-SANTIAGO, MD, JOSÉ ANEIROS-FERNÁNDEZ, MD, MARÍA SIERRA GIRÓN-PRIETO, MD, MARÍA ANTONIA FERNÁNDEZ-PUGNAIRE, PhD, RAMÓN NARANJO-SINTES, PhD

TREATMENT DIRECTED AT SYMPTOMS

Our patient received oral corticosteroids 0.5 mg/kg per day for 20 days, and the lesions resolved by 4 weeks.

Management of Henoch-Schönlein purpura is mainly directed at the symptoms, with oral hydration and nonsteroidal anti-inflammatory drugs. For severe cases, a short course of corticosteroids (0.5–1 mg/kg) may be used.

Although no controlled clinical trial has proven that Henoch-Schönlein purpura responds to corticosteroids, colchicine, or other drugs, corticosteroids are used most often, especially in patients with renal disease. Patients with severe renal insufficiency, abdominal pain, joint involvement, or bleeding should be hospitalized. Plasmapheresis³ has been used in severe cases.

HENOCH-SCHÖNLEIN PURPURA AND MALIGNANCY

During a follow-up evaluation 1 month later, our patient was diagnosed with adenocarcinoma of the breast. This highlights the value of a workup for cancer in adults with cutaneous vasculitis.

Cutaneous vasculitis can represent a paraneoplastic syndrome associated with a malignant tumor. The pathophysiology of this association is unclear, but one proposed mechanism is the exaggerated production of antibodies that react against tumor neoantigens, leading to the formation of immune complexes, or that occasionally recognize endothelial cells because of similarities with tumor antigens. Another theory is that abnormally high levels of inflammatory cytokines are produced by neoplastic cells or in response to decreased immune complex clearance.

Yet another theory is that hyperviscosity of the blood, seen in some cancers, increases the contact time for deposition of immune complexes and causes endothelial damage. Drugs used to treat cancer have also been reported to produce Henoch-Schönlein purpura.

Although hematologic malignancy is three to five times more common than solid tumors in patients with small-vessel vasculitis, the disease has been associated with solid tumors of the liver, skin, colon, and breast in adults over age 40.⁵ An evaluation for neoplasm is therefore reasonable in adults with Henoch-Schönlein purpura, as is an evaluation for tumor recurrence or metastasis if the patient has been previously treated for a malignant tumor.

Copyright© 2010 The Cleveland Clinic Foundation

REFERENCES

1. 1.
   1. Rieu P,
   2. Noël LH

   . Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris) 1999; 150:151–159.

   Medline
2. 2.
   1. Fretzayas A,
   2. Sionti I,
   3. Moustaki M,
   4. Nicolaidou P

   . Clinical impact of altered immunoglobulin levels in Henoch-Schönlein purpura. Pediatr Int 2009; 51:381–384.

   CrossRefMedline
3. 3.
   1. Donghi D,
   2. Schanz U,
   3. Sahrbacher U,
   4. et al.

   Life-threatening or organimpairing Henoch-Schönlein purpura: plasmapheresis may save lives and limit organ damage. Dermatology 2009; 219:167–170.

   CrossRefMedline
4. 4.
   1. Mitsui H,
   2. Shibagaki N,
   3. Kawamura T,
   4. Matsue H,
   5. Shimada S

   . A clinical study of Henoch-Schönlein purpura associated with malignancy. J Eur Acad Dermatol Venereol 2009; 23:394–401.

   CrossRefMedline
5. 5.
   1. Maestri A,
   2. Malacarne P,
   3. Santini A

   . Henoch-Schönlein syndrome associated with breast cancer. A case report. Angiology 1995; 46:625–627.

   CrossRefMedline

Skin Diseases and Conditions

SKINIPEDIA, your Skin Encyclopedia